Combined ranibizumab and stereotactic X-ray therapy shows promise in polypoidal choroidal vasculopathy

HAMBURG — Preliminary data  of a pilot study on combined ranibizumab and stereotactic X-ray therapy for polypoidal choroidal vasculopathy showed encouraging anatomical and visual acuity outcomes, according to a speaker here.  “PCV is frequently present in patients with neovascular AMD. Intravitreal injection of anti-VEGF has been shown to effectively reduce exudation, but does not lead to regression of polyps. We used [photodyamic therapy] to address this component, but results were poor and we had complications,” Ugo Introini, MD, said at the Euretina meeting. 

Full Story →